Pathologic and molecular features of uterine carcinosarcomas

Seminars in Diagnostic Pathology

Volumn 27, Issue 4, 2010, Pages 274-286

  Lopez Garcia, Maria Angeles ^a   Palacios, Jose ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

E cadherin; Endometrial carcinoma; Epithelial mesenchymal transition; Inmunohistochemistry; Uterine carcinosarcoma

Indexed keywords

CD34 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; EPITHELIAL MEMBRANE ANTIGEN; PROTEIN P16; VIMENTIN;

ARTICLE; CANCER EPIDEMIOLOGY; CANCER MORPHOLOGY; CANCER SURVIVAL; CLINICAL FEATURE; CLONAL VARIATION; DIFFERENTIAL DIAGNOSIS; EPITHELIAL MESENCHYMAL TRANSITION; GENE MUTATION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MESONEPHROMA; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RHABDOMYOSARCOMA; SQUAMOUS CELL CARCINOMA; UTERUS CARCINOMA; UTERUS SARCOMA;

CARCINOSARCOMA; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; PROGNOSIS; UTERINE NEOPLASMS;

EID: 78650215830     PISSN: 07402570     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.semdp.2010.09.005     Document Type: Article

References (95)

1. McCluggage W.G. Malignant biphasic uterine tumours: carcinosarcomas or metaplastic carcinomas?. J Clin Pathol 2002, 55:321-325.
2. Soslow R.A., Bissonnette J.P., Wilton A., et al. Clinicopathologic analysis of 187 high-grade endometrial carcinomas of different histologic subtypes: similar outcomes belie distinctive biologic differences. Am J Surg Pathol 2007, 31:979-987.
3. Gorai I., Doi C., Minaguchi H. Establishment and characterization of carcinosarcoma cell line of the human uterus. Cancer 1993, 71:775-786.
4. Gorai I., Yanagibashi T., Taki A., et al. Uterine carcinosarcoma is derived from a single stem cell: an in vitro study. Int J Cancer 1997, 72:821-827.
5. de Brito P.A., Silverberg S.G., Orenstein J.M. Carcinosarcoma (malignant mixed mullerian (mesodermal) tumor) of the female genital tract: immunohistochemical and ultrastructural analysis of 28 cases. Hum Pathol 1993, 24:132-142.
6. Jin Z., Ogata S., Tamura G., et al. Carcinosarcomas (malignant mullerian mixed tumors) of the uterus and ovary: a genetic study with special reference to histogenesis. Int J Gynecol Pathol 2003, 22:368-373.
7. Costa M.J., Vogelsan J., Young L.J. p53 gene mutation in female genital tract carcinosarcomas (malignant mixed mullerian tumors): a clinicopathologic study of 74 cases. Mod Pathol 1994, 7:619-627.
8. Dacic S., Finkelstein S.D., Sasatomi E., et al. Molecular pathogenesis of pulmonary carcinosarcoma as determined by microdissection-based allelotyping. Am J Surg Pathol 2002, 26:510-516.
9. Fujii H., Yoshida M., Gong Z.X., et al. Frequent genetic heterogeneity in the clonal evolution of gynecological carcinosarcoma and its influence on phenotypic diversity. Cancer Res 2000, 60:114-120.
10. Sarrio D., Rodriguez-Pinilla S.M., Hardisson D., et al. Epithelial-mesenchymal transition in breast cancer relates to the basal-like phenotype. Cancer Res 2008, 68:989-997.
11. Zeisberg M., Neilson E.G. Biomarkers for epithelial-mesenchymal transitions. J Clin Invest 2009, 119:1429-1437.
12. Peinado H., Olmeda D., Cano A. Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype?. Nat Rev Cancer 2007, 7:415-428.
13. Yoshida S., Furukawa N., Haruta S., et al. Expression profiles of genes involved in poor prognosis of epithelial ovarian carcinoma: a review. Int J Gynecol Cancer 2009, 19:992-997.
14. Pathology and Genetics of Tumours of the Breast and Female Genital Organs 2003, International Agency for Research of Cancer, Lyon. F.A. Tavassoli, P. Devilee (Eds.).
15. Garg G., Shah J.P., Kumar S., et al. Ovarian and uterine carcinosarcomas: a comparative analysis of prognostic variables and survival outcomes. Int J Gynecol Cancer 2010, 20:888-894.
16. Sabatino S.A., Stewart S.L., Wilson R.J. Racial and ethnic variations in the incidence of cancers of the uterine corpus, United States, 2001-2003. J Womens Health (Larchmt) 2009, 18:285-294.
17. Sherman M.E., Devesa S.S. Analysis of racial differences in incidence, survival, and mortality for malignant tumors of the uterine corpus. Cancer 2003, 98:176-186.
18. Schwartz S.M., Weiss N.S., Daling J.R., et al. Exogenous sex hormone use, correlates of endogenous hormone levels, and the incidence of histologic types of sarcoma of the uterus. Cancer 1996, 77:717-724.
19. Zelmanowicz A., Hildesheim A., Sherman M.E., et al. Evidence for a common etiology for endometrial carcinomas and malignant mixed mullerian tumors. Gynecol Oncol 1998, 69:253-257.
20. McCluggage W.G., Abdulkader M., Price J.H., et al. Uterine carcinosarcomas in patients receiving tamoxifen. A report of 19 cases. Int J Gynecol Cancer 2000, 10:280-284.
21. McCluggage W.G., McManus D.T., Lioe T.F., et al. Uterine carcinosarcoma in association with tamoxifen therapy. Br J Obstet Gynaecol 1997, 104:748-750.
22. Kloos I., Delaloge S., Pautier P., et al. Tamoxifen-related uterine carcinosarcomas occur under/after prolonged treatment: report of five cases and review of the literature. Int J Gynecol Cancer 2002, 12:496-500.
23. Clement P.B., Zubovits J.T., Young R.H., et al. Malignant mullerian mixed tumors of the uterine cervix: a report of nine cases of a neoplasm with morphology often different from its counterpart in the corpus. Int J Gynecol Pathol 1998, 17:211-222.
24. Grayson W., Taylor L.F., Cooper K. Carcinosarcoma of the uterine cervix: a report of eight cases with immunohistochemical analysis and evaluation of human papillomavirus status. Am J Surg Pathol 2001, 25:338-347.
25. Takeshima Y., Amatya V.J., Nakayori F., et al. Co-existent carcinosarcoma and adenoid basal carcinoma of the uterine cervix and correlation with human papillomavirus infection. Int J Gynecol Pathol 2002, 21:186-190.
26. Ferguson S.E., Tornos C., Hummer A., et al. Prognostic features of surgical stage I uterine carcinosarcoma. Am J Surg Pathol 2007, 31:1653-1661.
27. Amant F., Dreyer L., Makin J., et al. Uterine sarcomas in South African black women: a clinicopathologic study with ethnic considerations. Eur J Gynaecol Oncol 2001, 22:194-200.
28. Silverberg S.G., Major F.J., Blessing J.A., et al. Carcinosarcoma (malignant mixed mesodermal tumor) of the uterus. A Gynecologic Oncology Group pathologic study of 203 cases. Int J Gynecol Pathol 1990, 9:1-19.
29. Djordjevic B., Gien L.T., Covens A., et al. Polypoid or non-polypoid?. A novel dichotomous approach to uterine carcinosarcoma. Gynecol Oncol 2009, 115:32-36.
30. Bitterman P., Chun B., Kurman R.J. The significance of epithelial differentiation in mixed mesodermal tumors of the uterus. A clinicopathologic and immunohistochemical study. Am J Surg Pathol 1990, 14:317-328.
31. Sreenan J.J., Hart W.R. Carcinosarcomas of the female genital tract. A pathologic study of 29 metastatic tumors: further evidence for the dominant role of the epithelial component and the conversion theory of histogenesis. Am J Surg Pathol 1995, 19:666-674.
32. Costa M.J., Guinee D. CD34 immunohistochemistry in female genital tract carcinosarcoma (malignant mixed mullerian tumors) supports a dominant role of the carcinomatous component. Appl Immunohistochem Mol Morphol 2000, 8:293-299.
33. Oliva E. CD10 expression in the female genital tract: does it have useful diagnostic applications?. Adv Anat Pathol 2004, 11:310-315.
34. Klein W.M., Kurman R.J. Lack of expression of c-kit protein (CD117) in mesenchymal tumors of the uterus and ovary. Int J Gynecol Pathol 2003, 22:181-184.
35. Rushing R.S., Shajahan S., Chendil D., et al. Uterine sarcomas express KIT protein but lack mutation(s) in exon 11 or 17 of c-KIT. Gynecol Oncol 2003, 91:9-14.
36. Costa M.J., Khan R., Judd R. Carcinoma (malignant mixed mullerian [mesodermal] tumor) of the uterus and ovary. Correlation of clinical, pathologic, and immunohistochemical features in 29 cases. Arch Pathol Lab Med 1991, 115:583-590.
37. Ansink A.C., Cross P.A., Scorer P., et al. The hormonal receptor status of uterine carcinosarcomas (mixed mullerian tumours): an immunohistochemical study. J Clin Pathol 1997, 50:328-331.
38. Reid-Nicholson M., Iyengar P., Hummer A.J., et al. Immunophenotypic diversity of endometrial adenocarcinomas: implications for differential diagnosis. Mod Pathol 2006, 19:1091-1100.
39. Buza N., Tavassoli F.A. Comparative analysis of P16 and P53 expression in uterine malignant mixed mullerian tumors. Int J Gynecol Pathol 2009, 28:514-521.
40. Clement P.B., Scully R.E. Mullerian adenosarcoma of the uterus. A clinicopathologic analysis of ten cases of a distinctive type of mullerian mixed tumor. Cancer 1974, 34:1138-1149.
41. Clement P.B., Scully R.E. Uterine tumors with mixed epithelial and mesenchymal elements. Semin Diagn Pathol 1988, 5:199-222.
42. Gallardo A., Prat J. Mullerian adenosarcoma: a clinicopathologic and immunohistochemical study of 55 cases challenging the existence of adenofibroma. Am J Surg Pathol 2009, 33:278-288.
43. McCluggage W.G. Mullerian adenosarcoma of the female genital tract. Adv Anat Pathol 2010, 17:122-129.
44. Seidman J.D., Chauhan S. Evaluation of the relationship between adenosarcoma and carcinosarcoma and a hypothesis of the histogenesis of uterine sarcomas. Int J Gynecol Pathol 2003, 22:75-82.
45. Clement P.B. Mullerian adenosarcomas of the uterus with sarcomatous overgrowth. A clinicopathological analysis of 10 cases. Am J Surg Pathol 1989, 13:28-38.
46. Murray S.K., Clement P.B., Young R.H. Endometrioid carcinomas of the uterine corpus with sex cord-like formations, hyalinization, and other unusual morphologic features: a report of 31 cases of a neoplasm that may be confused with carcinosarcoma and other uterine neoplasms. Am J Surg Pathol 2005, 29:157-166.
47. Tornos C., Silva E.G., Ordonez N.G., et al. Endometrioid carcinoma of the ovary with a prominent spindle-cell component, a source of diagnostic confusion. A report of 14 cases. Am J Surg Pathol 1995, 19:1343-1353.
48. Altrabulsi B., Malpica A., Deavers M.T., et al. Undifferentiated carcinoma of the endometrium. Am J Surg Pathol 2005, 29:1316-1321.
49. Tafe L.J., Garg K., Chew I., et al. Endometrial and ovarian carcinomas with undifferentiated components: clinically aggressive and frequently underrecognized neoplasms. Mod Pathol 2010, 23:781-789.
50. Fadare O., Bonvicino A., Martel M., et al. Pleomorphic rhabdomyosarcoma of the uterine corpus: a clinicopathologic study of 4 cases and a review of the literature. Int J Gynecol Pathol 2010, 29:122-134.
51. McCluggage W.G., Lioe T.F., McClelland H.R., et al. Rhabdomyosarcoma of the uterus: report of two cases, including one of the spindle cell variant. Int J Gynecol Cancer 2002, 12:128-132.
52. Bague S., Rodriguez I.M., Prat J. Malignant mesonephric tumors of the female genital tract: a clinicopathologic study of 9 cases. Am J Surg Pathol 2004, 28:601-607.
53. Clement P.B., Young R.H., Keh P., et al. Malignant mesonephric neoplasms of the uterine cervix. A report of eight cases, including four with a malignant spindle cell component. Am J Surg Pathol 1995, 19:1158-1171.
54. George E., Lillemoe T.J., Twiggs L.B., et al. Malignant mixed mullerian tumor versus high-grade endometrial carcinoma and aggressive variants of endometrial carcinoma: a comparative analysis of survival. Int J Gynecol Pathol 1995, 14:39-44.
55. Yamada S.D., Burger R.A., Brewster W.R., et al. Pathologic variables and adjuvant therapy as predictors of recurrence and survival for patients with surgically evaluated carcinosarcoma of the uterus. Cancer 2000, 88:2782-2786.
56. Bland A.E., Stone R., Heuser C., et al. A clinical and biological comparison between malignant mixed mullerian tumors and grade 3 endometrioid endometrial carcinomas. Int J Gynecol Cancer 2009, 19:261-265.
57. Major F.J., Blessing J.A., Silverberg S.G., et al. Prognostic factors in early-stage uterine sarcoma. A Gynecologic Oncology Group study. Cancer 1993, 71:1702-1709.
58. Alektiar K.M., McKee A., Lin O., et al. Is there a difference in outcome between stage I-II endometrial cancer of papillary serous/clear cell and endometrioid FIGO grade 3 cancer?. Int J Radiat Oncol Biol Phys 2002, 54:79-85.
59. Inthasorn P., Carter J., Valmadre S., et al. Analysis of clinicopathologic factors in malignant mixed Mullerian tumors of the uterine corpus. Int J Gynecol Cancer 2002, 12:348-353.
60. Barwick K.W., LiVolsi V.A. Malignant mixed mullerian tumors of the uterus. A clinicopathologic assessment of 34 cases. Am J Surg Pathol 1979, 3:125-135.
61. Nielsen S.N., Podratz K.C., Scheithauer B.W., et al. Clinicopathologic analysis of uterine malignant mixed mullerian tumors. Gynecol Oncol 1989, 34:372-378.
62. Macasaet M.A., Waxman M., Fruchter R.G., et al. Prognostic factors in malignant mesodermal (mullerian) mixed tumors of the uterus. Gynecol Oncol 1985, 20:32-42.
63. Galaal K., Kew F.M., Tam K.F., et al. Evaluation of prognostic factors and treatment outcomes in uterine carcinosarcoma. Eur J Obstet Gynecol Reprod Biol 2009, 143:88-92.
64. Wada H., Enomoto T., Fujita M., et al. Molecular evidence that most but not all carcinosarcomas of the uterus are combination tumors. Cancer Res 1997, 57:5379-5385.
65. Abeln E.C., Smit V.T., Wessels J.W., et al. Molecular genetic evidence for the conversion hypothesis of the origin of malignant mixed mullerian tumours. J Pathol 1997, 183:424-431.
66. Lax S.F. Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification. Virchows Arch 2004, 444:213-223.
67. Taylor N.P., Zighelboim I., Huettner P.C., et al. DNA mismatch repair and TP53 defects are early events in uterine carcinosarcoma tumorigenesis. Mod Pathol 2006, 19:1333-1338.
68. Azueta A.G., Pallares J., Velasco A., et al. Endometrioid carcinoma of the endometrium: pathological and molecular features. Semin Diagn Pathol 2010.
69. Catasus L., Gallardo A., Cuatrecasas M., et al. Concomitant PI3K-AKT and p53 alterations in endometrial carcinomas are associated with poor prognosis. Mod Pathol 2009, 22:522-529.
70. Fleming G.F., Sill M.W., Darcy K.M., et al. Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2010, 116:15-20.
71. Kounelis S., Jones M.W., Papadaki H., et al. Carcinosarcomas (malignant mixed mullerian tumors) of the female genital tract: comparative molecular analysis of epithelial and mesenchymal components. Hum Pathol 1998, 29:82-87.
72. Mayall F., Rutty K., Campbell F., et al. p53 immunostaining suggests that uterine carcinosarcomas are monoclonal. Histopathology 1994, 24:211-214.
73. Robinson-Bennett B., Belch R.Z., Han A.C. Loss of p16 in recurrent malignant mixed mullerian tumors of the uterus. Int J Gynecol Cancer 2006, 16:1354-1357.
74. Szukala S.A., Marks J.R., Burchette J.L., et al. Co-expression of p53 by epithelial and stromal elements in carcinosarcoma of the female genital tract: an immunohistochemical study of 19 cases. Int J Gynecol Cancer 1999, 9:131-136.
75. Schipf A., Mayr D., Kirchner T., et al. Molecular genetic aberrations of ovarian and uterine carcinosarcomas-a CGH and FISH study. Virchows Arch 2008, 452:259-268.
76. Livasy C.A., Reading F.C., Moore D.T., et al. EGFR expression and HER2/neu overexpression/amplification in endometrial carcinosarcoma. Gynecol Oncol 2006, 100:101-106.
77. Cimbaluk D., Rotmensch J., Scudiere J., et al. Uterine carcinosarcoma: immunohistochemical studies on tissue microarrays with focus on potential therapeutic targets. Gynecol Oncol 2007, 105:138-144.
78. Reis-Filho J.S., Pinheiro C., Lambros M.B., et al. EGFR amplification and lack of activating mutations in metaplastic breast carcinomas. J Pathol 2006, 209:445-453.
79. Amant F., Vergote I. PTEN mutation analysis in uterine leiomyosarcomas and mixed mullerian sarcomas. Am J Obstet Gynecol 2002, 187:258.
80. Lancaster J.M., Risinger J.I., Carney M.E., et al. Mutational analysis of the PTEN gene in human uterine sarcomas. Am J Obstet Gynecol 2001, 184:1051-1053.
81. Murray S., Linardou H., Mountzios G., et al. Low frequency of somatic mutations in uterine sarcomas: a molecular analysis and review of the literature. Mutat Res 2010, 686:68-73.
82. Saegusa M., Hashimura M., Kuwata T., et al. Requirement of the Akt/beta-catenin pathway for uterine carcinosarcoma genesis, modulating E-cadherin expression through the transactivation of slug. Am J Pathol 2009, 174:2107-2115.
83. South S.A., Hutton M., Farrell C., et al. Uterine carcinosarcoma associated with hereditary nonpolyposis colorectal cancer. Obstet Gynecol 2007, 110:543-545.
84. Acloque H., Adams M.S., Fishwick K., et al. Epithelial-mesenchymal transitions: the importance of changing cell state in development and disease. J Clin Invest 2009, 119:1438-1449.
85. Thiery J.P., Acloque H., Huang R.Y., et al. Epithelial-mesenchymal transitions in development and disease. Cell 2009, 139:871-890.
86. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
87. Kloosterman W.P., Plasterk R.H. The diverse functions of microRNAs in animal development and disease. Dev Cell 2006, 11:441-450.
88. Burk U., Schubert J., Wellner U., et al. A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep 2008, 9:582-589.
89. Gregory P.A., Bert A.G., Paterson E.L., et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 2008, 10:593-601.
90. Korpal M., Kang Y. The emerging role of miR-200 family of microRNAs in epithelial-mesenchymal transition and cancer metastasis. RNA Biol 2008, 5:115-119.
91. Park S.M., Gaur A.B., Lengyel E., et al. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev 2008, 22:894-907.
92. Bracken C.P., Gregory P.A., Kolesnikoff N., et al. A double-negative feedback loop between ZEB1-SIP1 and the microRNA-200 family regulates epithelial-mesenchymal transition. Cancer Res 2008, 68:7846-7854.
93. Lena A.M., Shalom-Feuerstein R., Rivetti di Val Cervo P., et al. miR-203 represses "stemness" by repressing DeltaNp63. Cell Death Differ 2008, 15:1187-1195.
94. Spoelstra N.S., Manning N.G., Higashi Y., et al. The transcription factor ZEB1 is aberrantly expressed in aggressive uterine cancers. Cancer Res 2006, 66:3893-3902.
95. Castilla MÁ, Moreno-Bueno G, Romero-Pérez L, et al. Micro-RNA signature of the epithelial-mesenchymal transition in endometrial carcinosarcoma. J Pathol (in press).